Loading AI feed…
Harrow
Action, confidence, horizon, and decision blockers at a glance.
Fast scan of bull, bear, and watch items
High-level snapshot
Thesis highlights from the latest analysis
Scannable catalysts and supporting factors
Other notable items detected
Next few weeks
Months to a year
| Symbol | Summary |
|---|---|
| AUPH | AUPH is closer on market cap than on business mix; it is a loose specialty-biopharma comparison rather than a direct ophthalmic commercial peer, so relative valuation read-through is limited. |
| IBRX | IBRX is similarly close on market cap but is immuno-oncology-focused, making it a weak operating comp; it mainly frames how speculative mid-cap biotech capital can price rather than Harrow's ophthalmology execution. |
| REGN | REGN has major ophthalmology exposure but is much larger and more diversified; it is more useful as a therapeutic-area benchmark than as a valuation comp for Harrow. |
Internal and external references used in this analysis